by Amy Adams on June 16, 2011 at 8:30AM | 0 comments
CIRM grantee Robert Blelloch of the University of California, San Francisco won the 2011 Outstanding Young Investigator Award from the International Society for Stem Cell Research. The society's annual meeting is taking place now in Toronto.
Blelloch presented his research June 15 at 6pm and will participate in a press briefing at noon June 16. His work focuses on the role of small molecules called microRNAs and their role in stem cell biology and cancer.
by Amy Adams on November 17, 2010 at 9:29AM | 2 comments
Yesterday CIRM grantee Bruce Conklin gave his top four reasons why embryonic stem cells are so valuable and why federal funding for the work needs to be able to continue. Conklin, who is Senior Investigator Gladstone Institute of Cardiovascular Disease and professor at UCSF, studies heart rhythm defects by creating iPS cells from people genetically predisposed to have those defects, then maturing those into heart cells in a dish.
by Amy Adams on November 12, 2010 at 9:41AM | 1 comment
Nobel Prize winner Stanley Prusiner was one of the authors on a letter to the New York Times on October 27 advocating that congress pass legislation that "would raise the annual federal investment in Alzheimer's research to $2 billion, and require that the president designate an official whose sole job would be to develop and execute a strategy against Alzheimer's."
by Amy Adams on September 22, 2010 at 9:06AM | 0 comments
The University of California has now entered the stem cell funding legal fracas, filing a motion to participate in the pending lawsuit. In a statement, the UC Office of the President said they are the first institution to seek to intervene in the lawsuit:
by Amy Adams on August 16, 2010 at 3:27PM | 0 comments
CIRM grantees at University of California, San Francisco, have published a Cell Stem Cell paper explaining why blood-forming stem cells accumulate cancer-causing mutations with age. Basically, they found that inactivity is genetically risky for the cells.